Kids with new diabetes try inhaled insulin in new study
NCT ID NCT07224321
Summary
This study is testing whether an inhaled insulin called Afrezza, used with a daily long-acting insulin shot, is safe and effective for controlling blood sugar in young people (ages 10-18) who were just diagnosed with type 1 diabetes. It will measure how well the treatment keeps blood sugar in a healthy range and how satisfied the teens and their parents are with this approach. The main part of the study lasts 13 weeks, with an option to continue for up to 26 more weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Barbara Davis Center for Diabetes Young Adult Clinic
RECRUITINGAurora, Colorado, 80045, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Joslin Diabetes Center
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.